TrialLancet (London, England)2022

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.

Ruth L Goodall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.